FDA Panel Largely Pans Trial Data for Myopia Eye Drops
(MedPage Today) -- The regulatory status of a low-dose atropine eye drop formulation for myopia remained unresolved following a day-long FDA advisory committee meeting, but closing comments did not bode well for SYD-101.
The Dermatologic and Ophthalmic...
Read more »